Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 174

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 174
---
 damage to its reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against it in excess of, or outside of, its insurance coverage could have a material adverse effect on its business, financial condition and results of operations. NLS Risks Related to the Ownership of its Securities The market price of NLS Common Shares and Warrants may be highly volatile, and you may not be able to resell your shares or Warrants at or above the initial public offering price. The trading price of each of NLS Common Shares and Warrants is likely to be volatile. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of such securities: •unsatisfactory results of clinical trials; •announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; •announcements of therapeutic innovations or new products by NLS or its competitors; •adverse actions taken by regulatory authorities with respect to NLS’s clinical trials, manufacturing supply chain or sales and marketing activities; •changes or developments in laws or regulations applicable to the treatment of the symptoms of narcolepsy, ADHD, or any other indication that NLS may seek to develop, or the use of mazindol to treat any such indications; •any adverse changes to NLS’s relationship with manufacturers or suppliers; •any intellectual property infringement actions in which NLS may become involved; •announcements concerning NLS’s competitors or the pharmaceutical industry in general; •achievement of expected product sales and profitability or NLS’s failure to meet expectations; •NLS’s commencement of, or involvement in, litigation; •any major changes in NLS’s board of directors or management; •NLS’s ability to recruit and retain qualified regulatory, research and development personnel; 52 •legislation in the United States relating to the sale or pricing of pharmaceuticals; •the depth of the trading market in NLS Common Shares and Warrants; •economic weakness, including rising or sustained high interest rates and high inflation, or political instability in particular foreign economies and markets; •business interruptions resulting from a local or worldwide pandemic (such as the COVID -19pandemic), geopolitical instability (such as the war in Ukraine and Israel’s multi -frontwar), and other conditions beyond NLS’s control; •the granting or exercise of employee stock options or other equity awards; and •changes in investors’